Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients

被引：66

作者：

Hoff, Ana O. ^{[1
]}

Toth, Bela ^{[2
]}

Hu, Mimi ^{[3
]}

Hortobagyi, Gabriel N. ^{[4
]}

Gagel, Robert F. ^{[3
]}

机构：

[1] Univ Sao Paulo, Fac Med, Dept Endocrinol, Inst Canc Estado Sao Paulo, BR-05508 Sao Paulo, Brazil

[2] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA

来源：

BISPHOSPHONATES AND OSTEONECROSIS OF THE JAW | 2011年 / 1218卷

关键词：

Paget's disease; osteonecrosis of the jaw (ONJ); cancer; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS; MULTIPLE-MYELOMA PATIENTS; BREAST-CANCER; ZOLEDRONIC ACID; SKELETAL METASTASES; AMERICAN-SOCIETY; DOUBLE-BLIND; PHASE-III; PAMIDRONATE; NECROSIS;

D O I：

10.1111/j.1749-6632.2010.05771.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Osteonecrosis of the jaw (ONJ), previously an entity associated with radiation therapy to the head and neck, has been observed in patients treated with bisphosphonates. Patients with metastatic breast cancer and myelomatous bone disease, commonly treated with high-potency nitrogen-containing bisphosphonates for a prolonged period of time, have the greatest risk of ONJ development. The reported frequency of ONJ ranges from 0.6% to 6.2% in breast cancer and from 1.7% to 15% in patients with multiple myeloma. Osteonecrosis of the jaw has also been observed in patients with other cancers such as prostate cancer and in benign bone disorders such as osteoporosis and Paget's disease in which the incidence is low. Risk factors associated with the development of ONJ include dental extractions, length of bisphosphonate treatment, and the type of bisphosphonate used. In this review, we summarize the reported incidence and risk factors associated with ONJ.

引用

页码：47 / 54

页数：8

共 36 条

[1] Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents [J].

Aragon-Ching, Jeanny B. ;

Ning, Yang-Min ;

Chen, Clara C. ;

Latham, Lea ;

Guadagnini, Jean-Pierre ;

Gulley, James L. ;

Arlen, Philip M. ;

Wright, John J. ;

Parnes, Howard ;

Figg, William D. ;

Dahut, William L. .

CANCER INVESTIGATION, 2009, 27 (02) :221-226

[2] Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors [J].

Badros, A ;

Weikel, D ;

Salama, A ;

Goloubeva, O ;

Schneider, A ;

Rapoport, A ;

Fenton, R ;

Gahres, N ;

Sausville, E ;

Ord, R ;

Meiller, T .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :945-952

[3] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].

Bamias, A ;

Kastritis, E ;

Bamia, C ;

Moulopoulos, LA ;

Melakopoulos, L ;

Bozas, G ;

Koutsoukou, V ;

Gika, D ;

Anagnostopoulos, A ;

Papadimitriou, C ;

Terpos, E ;

Dimopoulos, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587

[4] American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma [J].

Berenson, JR ;

Hillner, BE ;

Kyle, RA ;

Anderson, K ;

Lipton, A ;

Yee, GC ;

Biermann, JS .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3719-3736

[5] Osteonecrosis of the jaw - Do biphosphonates pose a risk? [J].

Bilezikian, John P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2278-2281

[6] Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid [J].

Cetiner, Sedat ;

Sucak, Gulsan Turkoz ;

Kahraman, Sevil Altundag ;

Aki, Sahika Zeynep ;

Kocakahyaoglu, Benay ;

Gultekin, Sibel Elif ;

Cetiner, Mustafa ;

Haznedar, Rauf .

JOURNAL OF BONE AND MINERAL METABOLISM, 2009, 27 (04) :435-443

[7] A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma [J].

Corso, A. ;

Varettoni, M. ;

Zappasodi, P. ;

Klersy, C. ;

Mangiacavalli, S. ;

Pica, G. ;

Lazzarino, M. .

LEUKEMIA, 2007, 21 (07) :1545-1548

[8]

Dimopoulos MA, 2006, HAEMATOL-HEMATOL J, V91, P968

[9]

Durie BGM, 2005, NEW ENGL J MED, V353, P99

[10] Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies [J].

Fehm, T. ;

Beck, V. ;

Banys, M. ;

Lipp, H. P. ;

Hairass, M. ;

Reinert, S. ;

Solomayer, E. F. ;

Wallwiener, D. ;

Krimmel, M. .

GYNECOLOGIC ONCOLOGY, 2009, 112 (03) :605-609

← 1 2 3 4 →